Tags

Type your tag names separated by a space and hit enter

Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma.
Chest. 1994 Feb; 105(2):483-8.Chest

Abstract

Three inhalation formulations of ICI 204,219 were compared for antagonism of antigen-induced bronchoconstriction in 16 subjects with asthma who demonstrated reproducible hypersensitivity to allergen during screening challenges. Each subject received a single 0.2-mg dose of each formulation and was challenged with ragweed 30 min after administration of ICI 204,219 until the forced expiratory volume in 1 s (FEV1) decreased by 20 percent or the maximum allergen concentration (100 micrograms/ml) was reached. The majority of subjects tolerated 100 micrograms/ml of allergen without a 20 percent decrease in FEV1. Inhalation formulations of ICI 204,219 successfully inhibited bronchoconstriction in subjects with reproducible sensitivity to ragweed challenges.

Authors+Show Affiliations

Allergy Associates, Colorado Springs, Colo.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8306751

Citation

Nathan, R A., et al. "Inhaled ICI 204,219 Blocks Antigen-induced Bronchoconstriction in Subjects With Bronchial Asthma." Chest, vol. 105, no. 2, 1994, pp. 483-8.
Nathan RA, Glass M, Minkwitz MC. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest. 1994;105(2):483-8.
Nathan, R. A., Glass, M., & Minkwitz, M. C. (1994). Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest, 105(2), 483-8.
Nathan RA, Glass M, Minkwitz MC. Inhaled ICI 204,219 Blocks Antigen-induced Bronchoconstriction in Subjects With Bronchial Asthma. Chest. 1994;105(2):483-8. PubMed PMID: 8306751.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. AU - Nathan,R A, AU - Glass,M, AU - Minkwitz,M C, PY - 1994/2/1/pubmed PY - 1994/2/1/medline PY - 1994/2/1/entrez SP - 483 EP - 8 JF - Chest JO - Chest VL - 105 IS - 2 N2 - Three inhalation formulations of ICI 204,219 were compared for antagonism of antigen-induced bronchoconstriction in 16 subjects with asthma who demonstrated reproducible hypersensitivity to allergen during screening challenges. Each subject received a single 0.2-mg dose of each formulation and was challenged with ragweed 30 min after administration of ICI 204,219 until the forced expiratory volume in 1 s (FEV1) decreased by 20 percent or the maximum allergen concentration (100 micrograms/ml) was reached. The majority of subjects tolerated 100 micrograms/ml of allergen without a 20 percent decrease in FEV1. Inhalation formulations of ICI 204,219 successfully inhibited bronchoconstriction in subjects with reproducible sensitivity to ragweed challenges. SN - 0012-3692 UR - https://www.unboundmedicine.com/medline/citation/8306751/Inhaled_ICI_204219_blocks_antigen_induced_bronchoconstriction_in_subjects_with_bronchial_asthma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(16)47391-5 DB - PRIME DP - Unbound Medicine ER -